SCHEMBL9921469

SCHEMBL9921469

CCCC(=O)NCCN(CCC)CCN

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.46
DNM1 Q05193 2/20 0.44
CTSD P07339 1/20 0.39
FAAH O00519 1/20 0.39
SLC6A5 Q9Y345 2/20 0.38
KMT2A Q03164 1/20 0.37
HPGD P15428 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
NAAA Q02083 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13033284 0.96 CASP2 (0.48) CASP2DNM1CTSDFAAHSLC6A5
SCHEMBL9921397 0.88 KMT2A (0.45) DNM1KMT2AHPGDALDH1A1KDM4E
SCHEMBL14607021 0.87 CASP2 (0.57) CASP2DNM1CTSDFAAHHPGD
SCHEMBL13254848 0.86 CASP2 (0.46) CASP2DNM1CTSDFAAHSLC6A5
SCHEMBL15184973 0.86 CASP2 (0.46) CASP2DNM1CTSDFAAHSLC6A5
SCHEMBL10081612 0.86 CASP2 (0.46) CASP2DNM1CTSDFAAHSLC6A5
SCHEMBL9452842 0.83 DNM1 (0.66) CASP2DNM1FAAHSLC6A5NAAA
SCHEMBL8353089 0.83 DNM1 (0.66) CASP2DNM1FAAHSLC6A5NAAA
SCHEMBL10099851 0.82 DNM1 (0.42) CASP2DNM1FAAHSLC6A5KDM4E
SCHEMBL9921462 0.82 PAOX (0.46) KMT2AHPGDALDH1A1MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921111-B2 Polymer based polynucleotide transfection agents INTEZYNE TECHNOLOGIES (US) 2014-12-30 US disclosed
US-20140302607-A1 POLYMER BASED POLYNUCLEOTIDE TRANSFECTION AGENTS INTEZYNE TECHNOLOGIES, INC. (US) 2014-10-09 US disclosed
US-20120237565-A1 PEGYLATED POLYPLEXES CONTAINING TWO OR MORE DIFFERENT POLYMERS FOR POLYNUCLEOTIDE DELIVERY INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2012-09-20 US disclosed
US-20120148631-A1 PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2012-06-14 US disclosed
WO-2011130577-A1 CONTROLLED POLYPLEX ASSEMBLY INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2011-10-20 WO disclosed
US-20110256227-A1 CONTROLLED POLYPLEX ASSEMBLY INTEZYNE TECHNOLOGIES, INC. (US) 2011-10-20 US disclosed
US-20110229528-A1 PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2011-09-22 US disclosed
WO-2011113065-A2 PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120148631-A1 PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY PARN, PUF60, PARG CASP2 4848/4885DNM1 295/4885CTSD 4392/4885
US-20120237565-A1 PEGYLATED POLYPLEXES CONTAINING TWO OR MORE DIFFERENT POLYMERS FOR POLYNUCLEOTIDE DELIVERY PARN, PARG, PUF60 CASP2 4779/4885DNM1 430/4885CTSD 4392/4885
US-20110229528-A1 PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY PARN, PUF60, PARG CASP2 4848/4885DNM1 295/4885CTSD 4392/4885
US-20110256227-A1 CONTROLLED POLYPLEX ASSEMBLY PARG, PARN, PUF60 CASP2 4774/4885DNM1 787/4885CTSD 4722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.